First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers

NCT ID: NCT02978755

Last Updated: 2022-04-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 78 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-06-30
• Study Completion Date: 2020-06-10

Brief Summary

First in Human study, assessing the safety profile, the pharmacokinetics and preliminary antitumor activity of GM102, a new compound (a monoclonal antibody), in patients with previously treated gynecological cancers bearing the AMHRII (anti-mullerian Hormone Receptor II) receptor. The primary objective of the study is to determine the GM102 recommended dose.

Detailed Description

AMHRII, an embryonic receptor, is reexpressed in a subset of gynecological cancers. GM102 is a humanized low fucose monoclonal antibody with a high affinity to AMHRII receptor. GM102 acts through enhanced capability to engage immune effector cells (macrophages, natural killer (NK) cells) to trigger ADCC (antibody dependent cellular cytotoxicity) and phagocytosis of tumor cells.

Patients with gynecological tumors expressing AMHRII receptor on the tumor cells in archived tissue as determined prior to study entry will be eligible for C101 study.

C101 consists in a phase I part (dose and schedule escalation) and a phase Ib part (expansion).

The phase I part is designed to determine the recommended phase 2 dose (RP2D) using the classical 3+3 dose-finding design. In six successive escalating dose cohorts, patients will receive GM102 infusions every 2 weeks until progression or toxicity. In 4 additional cohorts, patients will receive GM102 infusions weekly until progression or toxicity and GM102 infusions combined with chemotherapy until progression or toxicity.

A Trial Steering Committee (TSC) will analyze and qualify the toxicities and will provide recommendations according to the dose administration rules defined in the protocol.

At the end of the phase I part, the RP2D will be determined, taking into account dose limiting toxicities (DLTs), overall toxicity, pharmacokinetics and pharmacodynamic effects of GM102.

The Phase Ib part of the study will confirm the tolerance of the selected dose (RP2D) and will assess antitumoral activity of GM102 in three parallel cohorts of patients with Sex Cord-Stromal tumors, and AMHRII positive ovarian and cervix cancers. Patients will be treated until progression or toxicity.

Conditions

Neoplasm, Gynecologic

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GM102 escalating doses

8 successive cohorts

Group Type: EXPERIMENTAL

GM102

Intervention Type: DRUG

GM102 escalating doses (phase1)

GM102 escalating doses + carboplatin+paclitaxel

2 successive cohorts

Group Type: EXPERIMENTAL

GM102 escalating doses

Intervention Type: DRUG

GM102 escalating doses combined with paclitaxel and carboplatin

GM102 recommended dose

3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers

Group Type: EXPERIMENTAL

GM102

Intervention Type: DRUG

GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)

Interventions

GM102

GM102 escalating doses (phase1)

Intervention Type: DRUG

GM102 escalating doses

GM102 escalating doses combined with paclitaxel and carboplatin

Intervention Type: DRUG

GM102

GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Locally advanced, or metastatic recurrent gynecological cancer, for whom no standard alternative therapy is available, having received at least one line of therapy and expressing AMHRII on tumor cells.
• If possible at least one lesion should be identified for 2 biopsies: a baseline biopsy and an under-treatment biopsy for AMHRII expression and GM102 pharmacodynamics evaluation.
• Available tumor block or at least 10 slides from formalin-fixed paraffin-embedded (FFPE) archival tissue.
• At least one measurable lesion by RECIST (Response Evaluation Criteria in Solid Tumors) on screening CT-scan.
• Written Informed Consent forms.
• Willing and able to comply with the trial requirements.
• Covered by healthcare insurance in accordance with local requirements.

For phase 1b, only patients with either Sex cord stromal tumors or epithelial ovarian cancer or cervix cancer will be eligible

Exclusion Criteria

• Age < 18 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status > 1
• Life expectancy < 12 weeks.
• Known or symptomatic brain metastasis (other than totally resected or previously irradiated and non-progressive/relapsing) or lepto-meningeal carcinomatosis.
• Concurrent treatment with any other anticancer therapy.
• Concurrent chronic corticosteroid treatment.
• Known severe anaphylactic or other hypersensitivity reactions secondary to a prior exposure to human antibodies or to any protein product.
• Washout period before treatment initiation: < 3 weeks or 5 times the half-life, whichever is shorter, for prior antitumor therapy (small molecules and/or antibody-drug conjugates, radiotherapy) or 6 weeks for monoclonal antibodies.
• Any active concomitant malignancy.
• Serious concomitant illness e.g. active infection requiring systemic antibiotic, antifungal or antiviral drug, or physical examination or laboratory abnormalities, that, in the opinion of the Investigator, would compromise protocol objectives.
• Poor bone marrow reserve as defined by neutrophils < 1.0 x 10E9/L or haemoglobin < 9.0 g/dL or platelet count < 100 x 10E9/L.
• Poor organ function as defined by any one of the following: left ventricular ejection fraction ≤ 40%, serum creatinine > 1.5 x upper limit of normal (ULN), total bilirubin > 1.5 x ULN, AST and ALT> 2.5 x ULN in the absence of liver metastasis or > 5 x ULN in case of documented liver metastasis.
• Non-resolution of any prior treatment related toxicity to < Grade 2, except for alopecia according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03.
• Pregnancy or breastfeeding.
• Patient with reproductive potential who do not agree to use an accepted effective method of contraception - investigator's judgment - during the study period and for at least 4 months following completion of study treatment.
• Patient participating in another clinical trial investigating a treatment during the study and within 30 days prior to first study treatment administration.
• Patient deprived of her liberty by a judicial or administrative decision, patient admitted to a hospital, social institution or who is under a measure of legal protection, patient hospitalized without consent or who is in an emergency situation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

GamaMabs Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexandra Leary, MD/PhD

Role: PRINCIPAL_INVESTIGATOR

Gustave Roussy center, Villejuif, France

Locations

Institut Bordet

Brussels, , Belgium

UZ Leuven

Leuven, , Belgium

CHU Besançon

Besançon, , France

Institut Bergonié

Bordeaux, , France

Centre Oscar Lambret

Lille, , France

Centre Leon Berard

Lyon, , France

Institut de cancerologie de Montpellier

Montpellier, , France

Institut de cancerologie de Lorraine

Nancy, , France

Institut Curie

Paris, , France

Institut Universitaire Cancer Toulouse - Oncopole

Toulouse, , France

Gustave Roussy

Villejuif, , France

Royal Marsden Hospital

London, , United Kingdom

Countries

Belgium; France; United Kingdom

References

Prat M, Le Naour A, Coulson K, Lemee F, Leray H, Jacquemin G, Rahabi MC, Lemaitre L, Authier H, Ferron G, Barret JM, Martinez A, Ayyoub M, Delord JP, Gladieff L, Tabah-Fisch I, Prost JF, Couderc B, Coste A. Circulating CD14high CD16low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression. J Immunother Cancer. 2020 Jun;8(1):e000472. doi: 10.1136/jitc-2019-000472.

Reference Type: DERIVED

PMID: 32503947 (View on PubMed)

Other Identifiers

C101

Identifier Type: -

Identifier Source: org_study_id